TENX Key Statistics, Chart & Performance
The current stock price of TENX is 13.3 USD. In the past month the price increased by 35.44%. In the past year, price increased by 113.14%.
TENX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About TENX
Company Profile
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 4 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Company Info
TENAX THERAPEUTICS INC
101 Glen Lennox Drive, Suite 300
Chapel Hill NORTH CAROLINA 27560 US
CEO: Anthony DiTonno
Employees: 4
Phone: 19198552100
TENAX THERAPEUTICS INC / TENX FAQ
What does TENAX THERAPEUTICS INC do?
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 4 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
What is the stock price of TENAX THERAPEUTICS INC today?
The current stock price of TENX is 13.3 USD. The price increased by 1.37% in the last trading session.
Does TENX stock pay dividends?
TENX does not pay a dividend.
How is the ChartMill rating for TENAX THERAPEUTICS INC?
TENX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for TENAX THERAPEUTICS INC?
TENAX THERAPEUTICS INC (TENX) has a market capitalization of 82.99M USD. This makes TENX a Micro Cap stock.
Can you provide the upcoming earnings date for TENAX THERAPEUTICS INC?
TENAX THERAPEUTICS INC (TENX) will report earnings on 2026-03-23, after the market close.
TENX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TENX. When comparing the yearly performance of all stocks, TENX is one of the better performing stocks in the market, outperforming 96.78% of all stocks.
TENX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TENX. No worries on liquidiy or solvency for TENX as it has an excellent financial health rating, but there are worries on the profitability.
TENX Financial Highlights
Over the last trailing twelve months TENX reported a non-GAAP Earnings per Share(EPS) of -1.13. The EPS increased by 93.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.14% | ||
| ROE | -45.03% | ||
| Debt/Equity | 0 |
TENX Forecast & Estimates
11 analysts have analysed TENX and the average price target is 25.76 USD. This implies a price increase of 93.65% is expected in the next year compared to the current price of 13.3.